BioAtla, Inc. financial data

Symbol
BCAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11085 Torreyana Road, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 414 % -43.2%
Debt-to-equity 74 % +129%
Return On Equity -170 % -120%
Return On Assets -97.5 % -67.2%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 48.3M shares +1.09%
Entity Public Float 91M USD +31.9%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 48.2M shares +1.07%
Weighted Average Number of Shares Outstanding, Diluted 48.2M shares +1.07%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 86.1M USD -8.74%
General and Administrative Expense 23.9M USD -9.96%
Operating Income (Loss) -110M USD +9.01%
Net Income (Loss) Attributable to Parent -105M USD +10.3%
Earnings Per Share, Basic -2.17 USD/shares +18.1%
Earnings Per Share, Diluted -2.17 USD/shares +18.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.7M USD -63.4%
Assets, Current 66.5M USD -62.1%
Property, Plant and Equipment, Net 1.13M USD -48.7%
Operating Lease, Right-of-Use Asset 1.01M USD -48.6%
Other Assets, Noncurrent 0 USD -100%
Assets 68.6M USD -61.8%
Accounts Payable, Current 1.36M USD -54.4%
Liabilities, Current 17.5M USD -48.1%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 37.3M USD -32.4%
Retained Earnings (Accumulated Deficit) -461M USD -29.4%
Stockholders' Equity Attributable to Parent 31.4M USD -74.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 31.4M USD -74.8%
Liabilities and Equity 68.6M USD -61.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.8M USD -36.1%
Net Cash Provided by (Used in) Financing Activities -13K USD +88.8%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 48.3M shares +1.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.7M USD -63.4%
Deferred Tax Assets, Valuation Allowance 85.6M USD +51%
Deferred Tax Assets, Gross 86.2M USD +49.5%
Operating Lease, Liability 1.66M USD -48.6%
Lessee, Operating Lease, Liability, to be Paid 1.69M USD -49.5%
Property, Plant and Equipment, Gross 7.68M USD -5.84%
Operating Lease, Liability, Current 1.66M USD +5.93%
Lessee, Operating Lease, Liability, to be Paid, Year Two 845K USD -49.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 849K USD +3.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32K USD -73.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 845K USD -49.9%
Deferred Tax Assets, Operating Loss Carryforwards 25M USD +43.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.6M USD +83%
Lessee, Operating Lease, Liability, to be Paid, Year Four 845K USD 0%
Operating Lease, Payments 1.52M USD -5.76%
Additional Paid in Capital 492M USD +2.37%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 240K USD -18.1%
Deferred Tax Assets, Net of Valuation Allowance 545K USD -41.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%